GLP-1 Diabetes Drugs Show Promise in Combating Addiction Across Multiple Substances

A major research study suggests that GLP-1 receptor agonists—medications originally developed to treat type 2 diabetes—may offer significant potential for preventing and reducing the harms of substance use disorders across alcohol, opioids, cocaine, nicotine, and cannabis. The findings, based on analysis of over 600,000 US veterans with type 2 diabetes, represent a notable shift in understanding how these increasingly popular medications work beyond weight loss and glucose control.

GLP-1 drugs such as semaglutide (marketed as Ozempic and Wegovy) and tirzepatide have become widespread in recent years, primarily recognised for their effectiveness in managing type 2 diabetes and obesity. What surprised researchers and patients alike was an unexpected side effect: individuals taking these medications reported a sudden loss of craving for alcohol, nicotine, and illicit drugs after years of unsuccessful attempts to quit. Some patients described it as an abrupt reduction in what researchers call “drug noise”—the relentless, intrusive craving that drives addiction.

The Washington University School of Medicine research team decided to investigate this phenomenon systematically. Rather than examining each substance separately, they asked a broader question: do GLP-1 medications work against substance use disorders universally, and can they reduce serious harms including overdose and drug-related death?

The study examined two groups. The first comprised 524,817 people with type 2 diabetes who had no prior substance use disorder diagnosis, comparing those who started a GLP-1 receptor agonist with those who started a different diabetes medication (a SGLT-2 inhibitor) that does not affect reward circuitry. The second group included 81,617 people with pre-existing substance use disorders.

For prevention, the results were striking. Compared to those on alternative diabetes medication, people taking GLP-1 drugs showed a 14% reduced risk of developing any substance use disorder. When examined by substance type, the protective effect was consistent: 18% reduction for alcohol, 14% for cannabis, 20% for cocaine and nicotine, and 25% for opioids. Across 1,000 GLP-1 users over three years, this translated to approximately six to seven fewer new diagnoses of substance use disorder.

For harm reduction in people already living with addiction, the findings were equally significant. After three years, GLP-1 use was associated with a 30% reduction in emergency department visits related to substance use, a 25% reduction in hospitalisations, a 40% reduction in overdose events, and a 50% reduction in drug-related deaths. This represented approximately 12 fewer serious harm events per 1,000 people taking GLP-1 medication.

The biological mechanism appears to centre on how these medications affect the brain’s reward and motivation systems. GLP-1 receptors are abundantly expressed throughout brain regions implicated in reward, motivation, stress, and addiction. At therapeutic doses, GLP-1 drugs cross the blood-brain barrier and modulate dopamine signalling in the mesolimbic pathways—the neural circuitry that addictive substances exploit to create craving and dependence.

Research suggests that GLP-1 medications do not target addiction to any single substance; rather, they appear to dampen the craving mechanism itself. This cross-substance signal points to a shared biological pathway underlying addiction—one that these drugs may interrupt regardless of the specific drug or alcohol involved.

It is important to note that whilst these findings are promising, this remains emerging research. The study used observational data from veterans and cannot definitively prove that GLP-1 drugs caused the reduction in substance use disorders, only that an association exists. Early clinical trials, particularly involving low-dose semaglutide for alcohol use disorder, have shown encouraging results, though more extensive research in diverse populations is needed.

Researchers emphasise that the mechanism through which GLP-1 medications reduce substance craving is not fully understood and requires further investigation. However, the consistency of findings across multiple substances suggests a genuine biological effect rather than coincidence or reporting bias.

• GLP-1 receptor agonists are associated with a 14% reduced risk of developing substance use disorders across all major classes studied, preventing approximately 6-7 new cases per 1,000 users over three years
• In people with existing addiction, GLP-1 medications were linked to 40% fewer overdoses and 50% fewer drug-related deaths, representing 12 fewer serious harm events per 1,000 users
• The protective effect appears to work by modulating dopamine signalling in the brain’s reward pathways, suggesting a common biological mechanism underlying addiction to different substances

What This Means for Kent Residents

For individuals across Kent struggling with substance use disorders, or those at risk of developing addiction, these findings may eventually offer a new avenue for prevention and treatment. Currently, GLP-1 medications are prescribed for type 2 diabetes and weight management through the NHS, and are available through providers including Kent and Medway NHS Trust. Whilst treatment of addiction is not yet an approved use for these drugs, the research highlights a potential new therapeutic approach that could complement existing addiction services provided by Kent’s specialist services and local GP practices. Anyone with concerns about substance use should speak with their GP, who can provide information about current evidence-based treatments and specialist support available through local services.